LEN vs NRIX · rev $34.19B vs rev $54.5M
LEN (LEN) versus Nurix Therapeutics Inc (NRIX) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
LEN currently screens at market cap $0. NRIX currently screens at market cap $1.77B.
Not investment advice. Open the LEN and NRIX stock pages for the full models.
Not investment advice.